BRAF and melanoma: To determine if the impact of mtRNA-driven, tumor cell autonomous Type I IFN production is sufficient to elicit an anti-tumor immune response in vivo, we turned to the classically immunologically cold B16 (BRAF wild type) melanoma model45.